Home /
Companies / McKesson Corporation dba McKesson Drug Company
McKesson Corporation dba McKesson Drug Company
FDA Regulatory Profile
Summary
- Total Recalls
- 6
- 510(k) Clearances
- 0
- Inspections
- 9
- Compliance Actions
- 0
Recent Recalls
| Number | Class | Product | Date |
|---|
| D-0850-2022 | Class II | Betamethasone Dipropionate Ointment USP, 0.05%* (Augmented) (Potency expressed as betamethasone), 15 | April 21, 2022 |
| D-0848-2022 | Class II | Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL), 50 mL bottle, Rx only, Manufactured by: | April 21, 2022 |
| D-0851-2022 | Class II | Erythromycin Topical Gel USP, 2%, Net Wt 60 g tube, Rx only, Manufactured by: Teligent Pharma, Inc. | April 21, 2022 |
| D-0849-2022 | Class II | Lidocaine Prilocaine Cream USP, 2.5%/2.5% Net Wt. 30 gram tube, Rx Only, Distributed by: McKesson Co | April 21, 2022 |
| D-0847-2022 | Class II | Halobetasol Propionate Ointment 0.05% Net Wt., 50 gram tube, Rx Only, Manufactured by: Teligent Phar | April 21, 2022 |
| D-0630-2021 | Class III | Levetiracetam Tablets USP, 250 mg UD 100 Tablets (10x10) boxes, Rx Only, Distributed By: McKesson Co | May 26, 2021 |